669 related articles for article (PubMed ID: 17889553)
1. The potential insulin sensitizing and glucose lowering effects of a novel indole derivative in vitro and in vivo.
Li YY; Wu HS; Tang L; Feng CR; Yu JH; Li Y; Yang YS; Yang B; He QJ
Pharmacol Res; 2007 Oct; 56(4):335-43. PubMed ID: 17889553
[TBL] [Abstract][Full Text] [Related]
2. Chebulagic acid from Terminalia chebula enhances insulin mediated glucose uptake in 3T3-L1 adipocytes via PPARγ signaling pathway.
Shyni GL; Kavitha S; Indu S; Arya AD; Anusree SS; Vineetha VP; Vandana S; Sundaresan A; Raghu KG
Biofactors; 2014; 40(6):646-57. PubMed ID: 25529897
[TBL] [Abstract][Full Text] [Related]
3. A novel indole derivative compound GY3 improves glucose and lipid metabolism via activation of AMP-activated protein kinase pathway.
Si M; Yan Y; Tang L; Wu H; Yang B; He Q; Wu H
Eur J Pharmacol; 2013 Jan; 698(1-3):480-8. PubMed ID: 23085267
[TBL] [Abstract][Full Text] [Related]
4. Subcutaneous abdominal adipose tissue subcompartments: potential role in rosiglitazone effects.
Walker GE; Marzullo P; Verti B; Guzzaloni G; Maestrini S; Zurleni F; Liuzzi A; Di Blasio AM
Obesity (Silver Spring); 2008 Sep; 16(9):1983-91. PubMed ID: 19186324
[TBL] [Abstract][Full Text] [Related]
5. Plasminogen activator inhibitor-1 modulates adipocyte differentiation.
Liang X; Kanjanabuch T; Mao SL; Hao CM; Tang YW; Declerck PJ; Hasty AH; Wasserman DH; Fogo AB; Ma LJ
Am J Physiol Endocrinol Metab; 2006 Jan; 290(1):E103-E113. PubMed ID: 16144810
[TBL] [Abstract][Full Text] [Related]
6. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
[TBL] [Abstract][Full Text] [Related]
7. Insulin-sensitizing effects of a novel alpha-methyl- alpha -phenoxylpropionate derivative in vitro.
Wu HS; Yu JH; Li YY; Yang YS; He QJ; Lou YJ; Ji RY
Acta Pharmacol Sin; 2007 Mar; 28(3):417-22. PubMed ID: 17303006
[TBL] [Abstract][Full Text] [Related]
8. Rosiglitazone increases cell surface GLUT4 levels in 3T3-L1 adipocytes through an enhancement of endosomal recycling.
Martinez L; Berenguer M; Bruce MC; Le Marchand-Brustel Y; Govers R
Biochem Pharmacol; 2010 May; 79(9):1300-9. PubMed ID: 20026082
[TBL] [Abstract][Full Text] [Related]
9. A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
Reifel-Miller A; Otto K; Hawkins E; Barr R; Bensch WR; Bull C; Dana S; Klausing K; Martin JA; Rafaeloff-Phail R; Rafizadeh-Montrose C; Rhodes G; Robey R; Rojo I; Rungta D; Snyder D; Wilbur K; Zhang T; Zink R; Warshawsky A; Brozinick JT
Mol Endocrinol; 2005 Jun; 19(6):1593-605. PubMed ID: 15831517
[TBL] [Abstract][Full Text] [Related]
10. Phytic acid and myo-inositol support adipocyte differentiation and improve insulin sensitivity in 3T3-L1 cells.
Kim JN; Han SN; Kim HK
Nutr Res; 2014 Aug; 34(8):723-31. PubMed ID: 25174657
[TBL] [Abstract][Full Text] [Related]
11. LT175 is a novel PPARα/γ ligand with potent insulin-sensitizing effects and reduced adipogenic properties.
Gilardi F; Giudici M; Mitro N; Maschi O; Guerrini U; Rando G; Maggi A; Cermenati G; Laghezza A; Loiodice F; Pochetti G; Lavecchia A; Caruso D; De Fabiani E; Bamberg K; Crestani M
J Biol Chem; 2014 Mar; 289(10):6908-6920. PubMed ID: 24451380
[TBL] [Abstract][Full Text] [Related]
12. Cilostazol ameliorates metabolic abnormalities with suppression of proinflammatory markers in a db/db mouse model of type 2 diabetes via activation of peroxisome proliferator-activated receptor gamma transcription.
Park SY; Shin HK; Lee JH; Kim CD; Lee WS; Rhim BY; Hong KW
J Pharmacol Exp Ther; 2009 May; 329(2):571-9. PubMed ID: 19221061
[TBL] [Abstract][Full Text] [Related]
13. Puerarin enhances adipocyte differentiation, adiponectin expression, and antioxidant response in 3T3-L1 cells.
Lee OH; Seo DH; Park CS; Kim YC
Biofactors; 2010; 36(6):459-67. PubMed ID: 20806284
[TBL] [Abstract][Full Text] [Related]
14. Magnolol enhances adipocyte differentiation and glucose uptake in 3T3-L1 cells.
Choi SS; Cha BY; Lee YS; Yonezawa T; Teruya T; Nagai K; Woo JT
Life Sci; 2009 Jun; 84(25-26):908-14. PubMed ID: 19376135
[TBL] [Abstract][Full Text] [Related]
15. Insulin-sensitizing effect of rosiglitazone (BRL-49653) by regulation of glucose transporters in muscle and fat of Zucker rats.
Kramer D; Shapiro R; Adler A; Bush E; Rondinone CM
Metabolism; 2001 Nov; 50(11):1294-300. PubMed ID: 11699047
[TBL] [Abstract][Full Text] [Related]
16. Hypoglycemic action of thiazolidinediones/peroxisome proliferator-activated receptor gamma by inhibition of the c-Jun NH2-terminal kinase pathway.
Díaz-Delfín J; Morales M; Caelles C
Diabetes; 2007 Jul; 56(7):1865-71. PubMed ID: 17416798
[TBL] [Abstract][Full Text] [Related]
17. 18F9 (4-(3,6-bis (ethoxycarbonyl)-4,5,6,7-tetrahydrothieno (2,3-c) pyridin-2-ylamino)-4-oxobutanoic acid) enhances insulin-mediated glucose uptake in vitro and exhibits antidiabetic activity in vivo in db/db mice.
Anandharajan R; Sayyed SG; Doshi LS; Dixit P; Chandak PG; Dixit AV; Brahma MK; Deshmukh NJ; Gupte R; Damre A; Suthar J; Padigaru M; Sharma SD; Nemmani KV
Metabolism; 2009 Oct; 58(10):1503-16. PubMed ID: 19608207
[TBL] [Abstract][Full Text] [Related]
18. Resistin and type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes.
McTernan PG; Fisher FM; Valsamakis G; Chetty R; Harte A; McTernan CL; Clark PM; Smith SA; Barnett AH; Kumar S
J Clin Endocrinol Metab; 2003 Dec; 88(12):6098-106. PubMed ID: 14671216
[TBL] [Abstract][Full Text] [Related]
19. Cilostazol increases 3T3-L1 preadipocyte differentiation with improved glucose uptake associated with activation of peroxisome proliferator-activated receptor-gamma transcription.
Park SY; Lee JH; Kim KY; Kim EK; Yun SJ; Kim CD; Lee WS; Hong KW
Atherosclerosis; 2008 Dec; 201(2):258-65. PubMed ID: 18355828
[TBL] [Abstract][Full Text] [Related]
20. PAM-1616, a selective peroxisome proliferator-activated receptor γ modulator with preserved anti-diabetic efficacy and reduced adverse effects.
Kim MK; Chae YN; Choi SH; Moon HS; Son MH; Bae MH; Choi HH; Hur Y; Kim E; Park YH; Park CS; Kim JG; Lim JI; Shin CY
Eur J Pharmacol; 2011 Jan; 650(2-3):673-81. PubMed ID: 20974124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
